Evaluation of cost-effectiveness of peginterferon plus ribavirin for chronic hepatitis C treatment and direct-acting antiviral agents among HIV-infected patients in the prison and community settings
Evaluation of cost-effectiveness of peginterferon plus ribavirin for chronic hepatitis C treatment and direct-acting antiviral agents among HIV-infected patients in the prison and community settings
复制标题
DOI：
10.1016/j.jmii.2018.10.002
复制
发表时间：
2019-08-01
影响因子：
7.4
通讯作者：
Bair, Ming-Jong
中科院分区：
文献类型：
--
作者：
Chen, Cheng-Pin;Cheng, Chien-Yu;Bair, Ming-Jong
背景资料：在台湾，大多数合并感染HIV的慢性丙型肝炎携带者是静脉注射毒品者和惩教机构的囚犯。聚乙二醇干扰素和利巴韦林（聚乙二醇干扰素/RBV）已成为标准的护理慢性丙型肝炎病毒（HCV）感染几十年。我们评估了国民健康保险研究数据库中1998年至2013年期间PegIFN/RBV的估计成本效果。材料和方法：这是一项观察性研究，研究期间为2010年至2016年，共有239例患者接受了PegIFN/RBV治疗。其中，156名患者在台北、桃园、台中、台东监狱的惩教所接受治疗，83名患者在社区接受治疗。结果：经多因素分析，在监狱中完成PegIFN/RBV治疗的患者（校正比值比[aOR]：4.56，95%可信区间[CI]：1.58-13.12，p = 0.005），HCVRNA水平、HCV
Background: In Taiwan, the majority of chronic hepatitis C carriers with HIV co-infection are intravenous drug users and inmates in correctional facilities. Peginterferon and ribavirin (PegIFN/RBV) have been the standard-of-care for chronic hepatitis C virus (HCV) infection more than decades. We evaluated the estimated cost-effectiveness of PegIFN/RBV from the National Health Insurance Research Database, covering the population of Taiwan from 1998 to 2013.Materials and methods: This is an observational study, and study during was 2010-2016 and a total of 239 patients were treated with PegIFN/RBV. Of them, 156 patients were treated in the correctional facilities of Taipei, Taoyuan, Taichung and Taitung prisons, and 83 patients were treated in communities. The cost-effectiveness was analyzed in regimens of PegIFN/RBV and direct-acting antiviral agents.Results: By multivariate analysis, the patients completed PegIFN/RBV in prison (adjusted odds ratio [aOR]: 4.56, 95% confidence interval [CI]: 1.58-13.12, p = 0.005), HCV RNA level